FDA Licenses Amgen Facility.Thousand Oaks-based Amgen Inc. said U.S. regulators licensed its new drug-manufacturing complex in Longmont, Colo., enabling it to step up production of its top-selling anemia anemia (ənē`mēə), condition in which the concentration of hemoglobin in the circulating blood is below normal. Such a condition is caused by a deficient number of erythrocytes (red blood cells), an abnormally low level of hemoglobin drug, Epogen. The Food and Drug Administration approved the plant, built on 22 acres of a 234-acre site and staffed by more than 275 employees. The 450,OOO-square-foot center will allow Amgen to produce three times the Epogen it makes at its plant in Thousand Oaks Thousand Oaks, residential city (1990 pop. 104,352), Ventura co., S Calif., in a farm area; inc. 1964. Avocados, citrus, vegetables, strawberries, and nursery products are grown. . U.S. sales of Epogen totaled $1.8 billion in 1999, accounting for more than half of Amgen's total sales of $3.3 billion. Amgen plans to use the new plant to manufacture its second-generation anemia drug NESP NESP Neuroendocrine Secretory Protein NESP Navy EHF SATCOM Program NESP Nurse Educator Scholarship Program NESP Navy EHF Satellite Program NESP National Environmental Studies Project NESP National Education Supercomputer Program , which is expected to win FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval early next year. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion